Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Dynasore is a cell-permeable, reversible small molecule inhibitor that noncompetitively inhibits the GTPase activity of dynamin 1 and dynamin 2 as well as Drp1 (mitochondrial dynamin-related protein 1), with an IC50 of approximately 15 μM. It blocks clathrin-mediated endocytosis by preventing the scission of vesicles from membranes, making it a widely used research tool in cell biology to study endocytosis and vesicular trafficking. Dynasore is selective for dynamins over other small GTPases such as MxA and Cdc42. It has been used in studies related to neuroscience (synaptic transmission), cancer research (tumor cell behavior and metastasis), drug delivery systems, and bioprocess optimization[2][3][4][5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on dynasore.